Inflammatory cytokine synthesis pathways

Inflammatory cytokine synthesis pathways comprise a network of intracellular signaling cascades that regulate the transcription, translation, and secretion of pro-inflammatory cytokines—such as interleukin-1 (IL-1), IL-6, IL-12, IL-18, tumor necrosis factor alpha (TNF-α), and interferon gamma (IFNγ)—from immune and non-immune cells in response to tissue injury, infection, or other stimuli[5][6]. These pathways are mainly triggered by the recognition of pathogen- or damage-associated molecular patterns (PAMPs/DAMPs) by pattern recognition receptors (PRRs), leading to downstream activation of nuclear factor kappa B (NF-κB), mitogen-activated protein kinases (MAPKs), and other transcription factors which drive cytokine gene expression[1][4]. While tightly regulated cytokine synthesis is essential for effective immune defense and tissue repair, uncontrolled or excessive cytokine production leads to pathologic inflammation as seen in sepsis, autoimmune diseases, cytokine storm syndromes, and cancer[1][6]. Therapeutically, these signaling pathways are not themselves drug targets, but components or mediators within them (such as cytokines, cytokine receptors, and key kinases) are established molecular targets for anti-inflammatory therapies[5][6][4]. Note: "Inflammatory cytokine synthesis pathways" is not the canonical name of a targetable molecule or receptor, but a description of cellular signaling involvement; therefore, this entry is marked as incorrect for the context of a therapeutic target.

Other names

Pro-inflammatory cytokine signaling pathwaysCytokine storm pathwaysCytokine production cascades

Blockade of cytokine receptors; Neutralization of cytokine ligands; Inhibition of intracellular signaling molecules (e.g., Janus kinases, IκB kinases)